Weekly Digests
‹ Back to November

What’s in your gut? The gut microbiome influences the efficacy of anti-PD-1 immunotherapy

November 22, 2017

Responses to immunotherapy vary due to a number of factors, and according to two recent papers published in Science, the gut microbiome is definitely one of them. Both papers indicated that diversity of bacteria and the abundance of certain types of bacteria can affect patients’ response to anti-PD-1 immunotherapy for some cancer types, and supported these conclusions with mouse studies.

In one of the studies, Gopalakrishnan et al. examined both the oral and gut microbiomes of patients with melanoma prior to and during anti-PD-1 immunotherapy, and found variance in microbiome diversity and composition between patients who responded to checkpoint blockade and those who did not. Pre-therapy samples from responders showed higher diversity, which correlated later with prolonged progression-free survival (PFS).

Along the same line, Routy et al. observed that dosing MCA-205 sarcoma-bearing mice with broad-spectrum antibiotics during anti-PD-1 or anti-PD-1/anti-CTLA-4 therapy significantly compromised the antitumor effect of the treatments. An analysis of human patients who had undergone treatment with anti-PD-1 for advanced non-small cell lung cancer, renal cell carcinoma, or urothelial carcinoma revealed that patients who had also taken antibiotics (for various common infections) shortly before or during anti-PD-1 therapy had significantly reduced PFS and overall survival compared to patients who did not take antibiotics.

Both research teams explored the overall profile of the gut microbiome and compared anti-PD-1 immunotherapy responders and non-responders. Gopalakrishnan et al. most notably observed that fecal samples from patients with melanoma who responded to anti-PD-1 were enriched for microbes from the Faecalibacterium genus, while non-responders were abundant in microbes from the Bacteroidales order. Prominence of Faecalibacterium specifically correlated with longer PFS, while an abundance of Bacteroidales correlated with shortened PFS. In patients with epithelial cancers, Routy et al. found Akkermansia muciniphila to correlate with clinical responses to checkpoint inhibition. Overrepresentation of this species at diagnosis was a predictor of patients who would benefit most from PD-1 inhibition. Enterococcus hirae, which has previously been reported to be associated with an immunomodulatory effect, was also observed at a higher incidence in responders.

To prove a causal, and not just a correlative link between the gut microbiome and response to checkpoint blockade, both research groups performed fecal microbiota transplantation (FMT) experiments in mice. Gopalakrishnan et al. observed that transplantation of stool from responders into germ-free mice (FMT-R mice) reduced the growth of engrafted tumors compared to transplantation of stool from non-responders (FMT-NR mice), while Routy et al. did not see a comparative reduction in the growth of tumors. Both research teams, however, saw delayed tumor growth in FMT-R compared to FMT-NR mice following PD-1 blockade. Gopalakrishnan et al. noted a higher density of tumor-infiltrating CD8+ T cells, and Routy et al. observed an accumulation of CXCR3+CD4+ T cells in tumors. Tumors in FMT-R mice from both experiments also showed upregulated PD-L1 expression, indicating the development of a hot tumor microenvironment.

To determine whether an unfavorable microbiome could be improved in mice, Routy et al. provided FMT-NR mice with an oral supplement of Akkermansia muciniphila or a combination of Akkermansia muciniphila and Enterococcus hirae. Both treatments restored the efficacy of PD-1 blockade, increased the ratio of CD4+ to Foxp3+ T cells, and induced dendritic cells to secrete IL-12 by increasing recruitment of CCR9+CXCR3+ CD4+ T cells to the tumor.

Delving into the mechanism underlying the microbiome’s contribution to the efficacy of checkpoint blockade, Gopalakrishnan et al. performed functional genomic profiling, which revealed differences in metabolic functions between responders and non-responders. Anabolic processes, including amino acid biosynthesis, were predominant in responders, while catabolic pathways were more common in non-responders. Immune profiling showed that on the systemic level, patients with favorable microbiomes had increased levels of effector CD4+ and CD8+ T cells and a preserved cytokine response to anti-PD-1 therapy, while patients with a higher abundance of unfavorable microbes in the gut had higher levels of Tregs and myeloid-derived suppressor cells in systemic circulation and a weakened cytokine response.

These two studies confirm that the gut microbiome has a role in mediating patient response to anti-PD-1 immunotherapy, and their results could quickly lead to novel clinical studies. If proven, strategies to avoid antibiotic use during checkpoint blockade therapy, support a diverse gut microbiome in patients, and supplement specific beneficial microbes could be simple to implement, and could swiftly lead to improved clinical outcomes in anti-PD-1 immunotherapy.

by Lauren Hitchings


Gopalakrishnan V., Spencer C.N., Nezi L., Reuben A., Andrews M.C., Karpinets T.V., Prieto P.A., Vicente D., Hoffman K., Wei S.C., Cogdill A.P., Zhao L., Hudgens C.W., Hutchinson D.S., Manzo T., Petaccia de Macedo M., Cotechini T., Kumar T., Chen W.S., Reddy S.M., Sloane R.S., Galloway-Pena J., Jiang H., Chen P.L., Shpall E.J., Rezvani K., Alousi A.M., Chemaly R.F., Shelburne S., Vence L.M., Okhuysen P.C., Jensen V.B., Swennes A.G., McAllister F., Sanchez E.M.R., Zhang Y., Le Chatelier E., Zitvogel L., Pons N., Austin-Breneman J.L., Haydu L.E., Burton E.M., Gardner J.M., Sirmans E., Hu J., Lazar A.J., Tsujikawa T., Diab A., Tawbi H., Glitza I.C., Hwu W.J., Patel S.P., Woodman S.E., Amaria R.N., Davies M.A., Gershenwald J.E., Hwu P., Lee J.E., Zhang J., Coussens L.M., Cooper Z.A., Futreal P.A., Daniel C.R., Ajami N.J., Petrosino J.F., Tetzlaff M.T., Sharma P., Allison J.P., Jenq R.R., Wargo J.A. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2017 Nov 2.

Routy B., Le Chatelier E., Derosa L., Duong C.P.M., Alou M.T., Daillère R., Fluckiger A., Messaoudene M., Rauber C., Roberti M.P., Fidelle M., Flament C., Poirier-Colame V., Opolon P., Klein C., Iribarren K., Mondragón L., Jacquelot N., Qu B., Ferrere G., Clémenson C., Mezquita L., Masip J.R., Naltet C., Brosseau S., Kaderbhai C., Richard C., Rizvi H., Levenez F., Galleron N., Quinquis B., Pons N., Ryffel B., Minard-Colin V., Gonin P., Soria J.C., Deutsch E., Loriot Y., Ghiringhelli F., Zalcman G., Goldwasser F., Escudier B., Hellmann M.D., Eggermont A., Raoult D., Albiges L., Kroemer G., Zitvogel L. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2017 Nov 2.

In the Spotlight...

Loss of function JAK1 mutations occur at high frequency in cancers with microsatellite instability and are suggestive of immune evasion

Analysis of a database of numerous solid tumors revealed recurrent pan-cancer frameshift mutations in JAK1, which primarily occurred in tumors with high mutation burden and microsatellite instability. The resulting JAK1 loss of function led to reduced interferon and IL-6 response, as well as reduced M1 macrophage and activated NK cell gene signatures, and likely represents a cancer adaptation that enables immune evasion.

Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent

An oncolytic adenovirus with improved tumor selectivity was used by Wang et al. to express the potent anti-tumor cytokine IL-12 intracellularly or as a secreted protein in a hamster pancreatic tumor model. Vectors expressing intracellular IL-12 led to cytokine release following infected cell lysis, were potent and safe in all disease models (subcutaneous, peritoneal, orthotopic), and induced significant, durable, and CD8+ T cell-dependent tumor control. In contrast, severe toxicity was observed with secreted IL-12 due to increased induction of inflammatory cytokines.

Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer

Utilizing sets of pancreatic cancer patients who differed significantly in median survival (6 years vs. 0.8 months), Balachandran et al. demonstrated that the long-term survivors exhibited superiority for multiple markers of immune activation, and that neoantigen load and either CD8+ T cell infiltration or TCR polyclonality were correlated with longer survival. A neoantigen quality score, based on molecular mimicry to known epitopes from infectious agents, independently stratified patients, suggesting a possible evolutionary dynamic sculpting the TCR repertoire.

A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy

Based on examples from infectious disease studies, Luksza et al. built a fitness model describing the evolutionary dynamics of multi-clonal tumor growth under immune pressure from neoantigens. They used data sets from genome-sequenced patients with known survival outcomes following checkpoint therapy to infer parameters related to neoantigen quality, as defined by the product of amplitude (the ratio of predicted wild type to mutant affinity) and recognition (a measure of alignment of the neoepitope to known TCR-recognized epitopes).

Generation of higher affinity T cell receptors by antigen-driven differentiation of progenitor T cells in vitro

Schmitt et al. developed a method of creating higher-affinity TCRs by in vitro maturation of hematopoietic progenitor cells that were transduced with only the TCRα chain of a known antigen-specific TCR on antigen-expressing feeder cells. Following T cell differentiation and natural Tcrb gene rearrangement, TCRβ chains were isolated from cells pre-enriched for target antigen-specificity and paired with the parental TCRα to create enhanced-affinity TCRs.

Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events

Ishihara et al. conjugated the heparin-binding domain of placenta growth factor-2 (PlGF-2123-144) to αCTLA-4 and αPD-L1 antibodies and demonstrated that peritumoral injection of PlGF-2123-144-αCTLA-4 + PlGF-2123-144-αPD-L1 into mice with melanoma or breast cancer enhanced local and systemic antitumor immunity, prolonged survival, and reduced the risk of systemic side effects compared with unconjugated antibodies by binding to the extracellular matrix and retaining antibodies within the tumor.

Everything New this Week In...

Close Modal

Small change for you. Big change for us!

This Thanksgiving season, show your support for cancer research by donating your change.

In less than a minute, link your credit card with our partner RoundUp App.

Every purchase you make with that card will be rounded up and the change will be donated to ACIR.

All transactions are securely made through Stripe.